n the past few years, novel components of the renin-angiotensin system (RAS) have been described, including the prorenin/ renin receptor, 1 angiotensin-converting enzyme-2 (ACE2), 2,3 and Mas.
I ACE/angiotensin II/angiotensin II type 1 receptor axis. 2, 12 Here, we describe the identification and characterization of a novel peptide of the renin-angiotensin system, the heptapeptide, AlaArg-Val-Tyr-Ile-His-Pro, alamandine, in rats, mice, and humans.
Methods

Forming of Alamandine by ACE2
Angiotensin A (10 µmol/L) was incubated with hACE2 (10 nmol/L). After the reaction and evaporation, angiotensin peptides were analyzed by mass spectrometry (matrix-assisted laser desorption ionization-time-of-flight/time-of-flight).
Alamandine Detection in Blood
Plasma preparation, size-exclusion chromatography, isolation in mass spectrometry, synthesis, and detection of peptide were described previously. 13 
Aortic Rings Assay
The vessels were precontracted with submaximal concentrations of phenylephrine (0.1 µmol/L). Agonists were added in increasing cumulative concentrations once the response to phenylephrine had stabilized. To study the mechanism of alamandine vasorelaxation, the following compounds were used: L-NAME, A-779, D-Pro 7 -Ang-(1-7), PD123319, and β-alanine.
Caudal Ventrolateral Medulla and Rostral Ventrolateral Medulla Microinjections
Unilateral microinjections of Ang-(1-7), alamandine, A-779, D-Pro 7 -Ang-(1-7), or vehicle (100 nL) were made over a 20-to 30-s period into the caudal ventrolateral medulla or rostral ventrolateral medulla of urethane-anesthetized Fisher rats.
Cell Culture
Transfected and nontransfected Chinese hamster ovary (CHO) cells and A549 human lung adenocarcinoma cells and DU 145 (prostate cancer cell line) were grown in DMEM-F12 medium (Sigma, Steinheim, Germany) supplemented with 10% fetal bovine serum, 100 μg/mL penicillin, and 100 U/mL streptomycin in a humidified incubator with 5% CO 2 and 95% room air.
Fluorescent Binding in Mas-Related G-proteinCoupled Receptor, Member D-Transfected Cells
Binding of fluorescent-labeled alamandine was tested in Mas-related G-protein-coupled receptor, member D-stably transfected CHO cells (CHO-MrgD). Fluorescent-labeled alamandine (0.01 μmol/L) was incubated for 30 minutes at room temperature alone or 5 minutes after preincubation with nonfluorescent alamandine (1 μmol/L, nonspecific binding),
(1 μmol/L), and the angiotensin II type 2 receptor (AT 2 R) antagonist PD123319 (1 μmol/L). Relative fluorescence measurements were performed by laser scanning confocal microscopy.
Evaluation of Nitric Oxide Release From CHO Cells
Nitric oxide (NO) release from transfected and nontransfected CHO cells was evaluated using the NO indicator 4-amino-5-methylamino-2,7-difluorofluorescein diacetate (DAF-FM).
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Inclusion Complex Preparation
The inclusion compound HPβCD/alamandine was prepared as previously described 15 (see also Online Figure IIIA-IIIC).
Effects of Oral Administration of HPβCD-Alamandine in Isoproterenol-Treated Rats
The protocol used for treatment with isoproterenol and the inclusion compound was the same as the one described previously.
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Effects of Oral Administration of HPβCD-Alamandine in Conscious Hypertensive Rats
Spontaneously hypertensive rats were instrumented for acute blood pressure recording as described previously. 14 After oral administration of the inclusion compound (132 µg/kg equivalent to 50 µg/kg of alamandine) or vehicle (HPβCD, 82 µg/kg), mean arterial pressure and heart rate were continuously recorded for 5 hours.
Results
Using mass spectrometry ( Figure 1A ) we have identified alamandine as a product of the catalytic hydrolysis of the octapeptide Ala 1 -AngII (angiotensin A) 13 by human ACE2. We also demonstrate that alamandine can be formed in the rat heart after Ang-(1-7) perfusion ( Figure 1B-1J ) with the use of selected reaction monitoring-mass spectrometry. 17 This indicates that the cardiac tissue contains all necessary components to promote the decarboxylation of the Ang-(1-7) N-terminal aspartate amino acid residue. Moreover, we show that alamandine is an endogenous peptide of this tissue ( Figure 1I ). Next, we determined if this peptide is also present in human blood. As shown in Online Figure IA through ID, alamandine circulates in human blood; and consistent with previous observations for angiotensin A, 13 our data revealed that nephropathic patients have increased plasmatic concentration of alamandine (Online Figure IE) .
The sequence of alamandine is very similar to Ang-(1-7), differing only by the presence of an alanine residue in place of an aspartate residue in the amino terminus. This structural modification (Online Figure IF) is because of a decarboxylation of the aspartate radical group, which has already been reported for angiotensin II. 13 Because of structural similarity between alamandine and Ang-(1-7), we decided to test whether the biological actions of these 2 peptides were similar, too. As shown in Figure 2A , and previously reported for Ang-(1-7), 4,10 alamandine produces endothelial-dependent vasorelaxation in aortic rings from FVB/N mice. Similar data were obtained in aortic rings from Wistar rats (data not shown). Accordingly, the alamandine-induced vasorelaxation was attenuated by pretreatment with the nitric oxide synthase inhibitor, L-NAME ( Figure 2B ). Strikingly, treatment with the Mas antagonist, A-779, did not block the alamandine-induced vasorelaxation ( Figure 2C ) as previously described for Ang-(1-7). 4, 14 In addition, the alamandine-induced vasorelaxation was preserved in aortic rings of Mas-deficient mice ( Figure  2D ). These observations suggest that Mas is not a putative alamandine receptor. Therefore, we conclude that alamandine is not a Mas agonist, although the vascular effects of this novel RAS peptide resemble those elicited by Ang-(1-7).
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angiotensin-converting enzyme-2
AT 2 R angiotensin II type 2 receptor MrgD Mas-related G-protein-coupled receptor, member D RAS renin-angiotensin system Figure 1 . Formation of alamandine by recombinant human angiotensin-converting enzyme-2 (ACE2) and in the isolated rat heart. A, ACE2 forms alamandine from angiotensin A (Ang A). Ang A was incubated with rhACE2 and the assay product was analyzed by matrix-assisted laser desorption ionization-time-of-flight/time-of-flight mass spectrometry. Top, Negative control (Ang A without rhACE2). Bottom, Mass spectrometry (MS) spectrum observed after 15 minutes of incubation. B, Table containing the transitions monitored to detect alamandine or angiotensin 1 to 7 [Ang-(1-7)]. C to E, The chromatogram profiles of the selected transition ions from Ang-(1-7). F to I The profiles for the alamandine transitions. C, 3×10 −15 mol of synthetic Ang-(1-7) in 0.1% formic acid. D, Isolated heart was perfused with Krebs solution (NaCl 118; KCl 4.7; KH 2 PO 4 0.9; MgSO 4 1.1; CaCl 2 2.5; NaHCO 3 
−6 mol/L Ang-(1-7). The collected sample was desalted and resuspended with 0.1% formic acid. It is possible to note that because of matrix interactions, the Ang-(1-7) transitions elute slightly later. E, Isolated heart was perfused with Krebs solution without Ang-(1-7). It was possible to detect all Ang-(1-7) transitions in the expected retention time, indicating the presence of endogenous Ang-(1-7) in the heart. F, 3×10 −15 mol of synthetic alamandine in 0.1% formic acid. G, Isolated heart was perfused with Krebs solution containing 10 −6 mol/L Ang-(1-7). It was possible to detect all the transitions of the alamandine, indicating that this peptide can be formed in the heart after Ang-(1-7) perfusion. H, 3×10 −15 mol of synthetic alamandine was spiked in the perfused heart solution to confirm the later retention time of alamandine transition because of matrix interference observed in (G). I, Isolated heart was perfused with Krebs solution without Ang-(1-7). It was possible to detect the transitions of the alamandine being eluted in the expected retention time, suggesting that alamandine is heart endogenous peptide. All experiments were performed with 2 biological replicates. J, Detection of alamandine in heart using selected reaction monitoring mass spectrometry (SRM-MS). Typical SRM method performed in a triple quadrupole MS. In the Q1, the parental ions are selected based on their mass-to-charge (m/z) ratio. The selected parental ions are fragmented in the collision cell Q2 and the fragment ions (transitions) are selected and mass-resolved in the Q3.
Studies have shown that in some circumstances Ang-(1-7) effects are not blocked by A-779, but can be blocked by another Ang-(1-7) antagonist, D-Pro 7 -Ang-(1-7).
18 -20 We next tested whether this antagonist could also block alamandine effects. Intriguingly, D-Pro 7 -Ang-(1-7) completely blocked the vasorelaxation produced by alamandine in mice aortic rings ( Figure 2E ). To ascertain whether this blockade was not limited to vessels, we performed experiments using microinjection of alamandine in central areas critically involved in blood pressure control, the caudal and rostral ventrolateral medulla. As shown in Figure  2G through 2J, both Ang-(1-7) and alamandine produced a pressor effect when microinjected in the rostral ventrolateral medulla and a depressor effect when microinjected into the caudal ventrolateral medulla of anesthetized Fisher rats. However, although the effect of Ang- (1-7) was altered by co-microinjection of A-779 and D-Pro 7 -Ang-(1-7), as observed in blood vessels, the effect of alamandine was only blocked by D-Pro 7 -Ang-(1-7). Besides being a Mas agonist, Ang-(1-7) has been reported to be a weak agonist of the Mas-related receptor, MrgD. 21 Therefore, we hypothesized that alamandine could be a possible endogenous ligand for MrgD. The amino acid β-alanine has been reported to be an agonist of MrgD; however, the effective concentration of β-alanine in MrgD-transfected cells is considerably high (10 -3 to 10 -6 mol/L). 22, 23 We first tested whether β-alanine and alamandine could interact in blood vessels. As shown in Figure 2F , β-alanine did not induce a direct relaxing effect in aortic rings. However, preincubation of aortic rings with β-alanine (10 -7 mol/L) abolished the vasorelaxation induced by alamandine in aortic rings of FVB/N mice. To further address the role of MrgD in the alamandine effects, we performed binding and functional studies in human MrgD-transfected cells (see online Data Supplement). For the binding experiments we used mono-5-(and-6)-carboxyfluorescein, FAM-labeled alamandine. As shown in Figure  3A through 3B, fluorescent-labeled alamandine specifically binds to MrgD-stably transfected CHO cells. No significant binding was observed in nontransfected CHO or Mas-stably transfected CHO cells ( Figure 3A) . Similar with the data obtained in aortic rings and central microinjection experiments, the binding of alamandine to MrgD-transfected cells was competed by D-Pro 7 -Ang-(1-7) and β-alanine but not by A-779 ( Figure 3A-3B) . To verify whether the binding of alamandine to MrgD-transfected cells would produce a functional response, we evaluated NO release using DAF.
14 Incubation with alamandine led to NO release in MrgDtransfected cells but not in Mas-transfected cells or in nontransfected CHO cells ( Figure 3E ).
PD123319 is a putative AT 2 R antagonist [24] [25] [26] and has been reported to block some of the Ang-(1-7) effects. 27, 28 In wildtype animals, PD123319 blocked the alamandine effects in aortic rings ( Figure 3C ). However, alamandine continues to induce vasorelaxation in aortic rings isolated from AT 2 R KO mice ( Figure 3D ), excluding a role for AT 2 R in the alamandine vascular effects. When alamandine was tested in the presence of PD123319 (10 -7 mol/L), its vasorelaxation-induced effect in AT 2 R KO mice was abolished ( Figure 3D ). These findings indicate that PD123319 binds to another receptor sensitive to alamandine. Indeed, PD123319 efficiently competed the binding of alamandine to MrgD-transfected CHO cells (Figure 3A-3B). Taken together, these findings are strong evidence that in addition to be an AT 2 R antagonist, PD123319 is also a MrgD antagonist/ligand.
We next tested whether alamandine could influence the growth of human tumoral cells. As shown in the Online Figure IIA through IIB, alamandine had no noticeable proliferative or antiproliferative effect in the human tumoral cell lines A549 and DU145, which express MrgD (Online Figure   IID) . Similar results were obtained with β-alanine (Online Figure IIA-IIB) .
Finally, we evaluated the potential therapeutic application of alamandine by including it in HP-β cyclodextrin 15, 16 (Online Figure IIIA-IIIC) . A single oral administration of the inclusion compound alamandine/HP-β cyclodextrin produced a long-term antihypertensive effect in spontaneously hypertensive rats ( Figure 4A ). In addition, a remarkable decrease Figure 4 . Effect of the inclusion compound alamandine/HPβCD in spontaneously hypertensive rats (SHR) and on cardiac fibrosis. A, B, SHR. The baseline blood pressure (A) and heart rate (B) were recorded for at least 90 minutes, and the baseline values were calculated as the average of 5 points during this time. After that, the SHR received a single oral dose of vehicle (HPβCD; 82 µg/kg) or HPβCD/alamandine (132 µg/kg, equivalent to 50 µg/kg of alamandine) by gavage. Bars represent the difference between values before and after treatment, at every 10 min after gavage. *P<0.05 alamandine vs vehicle (2-way ANOVA followed by Bonferroni post hoc test). C to E, The effect of alamandine on the isoproterenol-induced increase in collagen I, collagen III, and fibronectin, respectively, in heart tissue of Wistar rats was evaluated by confocal microscopy on a Zeiss LSM 510 META laser scanning confocal microscope excited at 488 nm with an argon-ion laser (oil-immersion objective lens, ×63). F, First column, alamandine reduces collagen I; second column, alamandine reduces collagen III; and third column, alamandine reduces fibronectin.*P<0.05 vs isoproterenol+water; **P<0.01 vs isoproterenol+water; and ***P<0.001 vs isoproterenol+water (1-way ANOVA followed by the Bonferroni post hoc test). MAP indicates mean arterial pressure.
in collagen I, III, and fibronectin accumulation was observed in isoproterenol-treated rats receiving 50 µg/kg of alamandine once a day ( Figure 4B-4E) .
In summary, we here report the identification of alamandine, a novel RAS hormone. Alamandine circulates in human blood and presents unique properties. Its biological activities resemble those of Ang-(1-7), including vasodilatation, antihypertensive effect in spontaneously hypertensive rats, and central cardiovascular effects. However, unlike Ang-(1-7), these effects are not mediated by binding to Mas. We identified a novel RAS-related receptor, MrgD, which is the binding site for alamandine. This receptor can be blocked by D-Pro 7 -Ang-(1-7), and its identification solves some earlier discrepant findings with the Mas antagonist A-779. [18] [19] [20] This observation is in line with our finding that Ang-(1-7) can be processed to alamandine in the isolated rat heart. Furthermore, we demonstrated that human ACE2 forms alamandine from angiotensin A, reinforcing the central role of this enzyme in the processing of angiotensin peptides. A simplified updated RAS cascade based on our present findings is presented in Online Figure IV .
It is pertinent to point out that previous observations suggesting a physiological or pathophysiological role for AT 2 R or its participation in the effects of Ang-(1-7), based on the use of PD123319, must be reevaluated in light of our current data.
Furthermore, recent data suggested a proliferative role for MrgD, which in contrast to what has been proposed in the past, 29 is not expressed exclusively in nociceptive sensory neurons 21, 29, 30 (Online Figure V) . However, we could not find any evidence for proliferative or antiproliferative activity of alamandine and of β-alanine in 2 different human tumoral cell lines, which also express MrgD (Online Figure IIA-IIB) .
The fact that the new RAS hormone alamandine can be easily administered orally as a HPβCD inclusion compound and produced antihypertensive effects in spontaneously hypertensive rats and pronounced cardioprotective effects in isoproterenol-treated rats, opens new perspectives for exploring the therapeutic potential of angiotensin-(1-7)-related peptides. The identification of 2 novel components of the RAS, alamandine and its receptor, will be important for improving our understanding of the physiological and pathophysiological role of the this key regulatory system.
